JNJ240712P110000
- 0.01
- 0.000.00%
Johnson & Johnson Newsroom
Morgan Stanley Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $167
Morgan Stanley analyst Terence Flynn maintains $Johnson & Johnson(JNJ.US)$ with a hold rating, and maintains the target price at $167.According to TipRanks data, the analyst has a success rate of 64.8
Johnson & Johnson (JNJ.US) announced the acquisition of Yellow Jersey will bring a cost impact of 1.25 billion US dollars, it is expected to dilute this year's adjusted EPS by 0.56 US dollars.
Johnson & Johnson announced on Thursday that the acquisition of Yellow Jersey Therapeutics will result in an expense impact of approximately $1.25 billion.
J&J to Recognize $1.25B Impact From Yellow Jersey Acquisition
Express News | Johnson & Johnson Completes The Acquisition Of Yellow Jersey, A Demerged Subsidiary Of Numab Therapeutics To Secure The Global Rights To Nm26, In An All-cash Transaction Of Approximately $1.25 Billion, As Announced On May 28, 2024
Express News | Johnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis With the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of Nm26
Wells Fargo Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $163
Wells Fargo analyst Larry Biegelsen maintains $Johnson & Johnson(JNJ.US)$ with a hold rating, and maintains the target price at $163.According to TipRanks data, the analyst has a success rate of 58.1%
Johnson & Johnson Faces MedTech Challenges But Is 'On Track' to Meet 2024 Guidance, Goldman Says
U.S. pharma giant Johnson & Johnson (NYSE:JNJ) will report its second-quarter 2024 earnings on Wednesday, July 17.As per data from Benzinga Pro, analysts estimate sales of $22.29 billion and
Citi Research's AI Hedge Stocks - Part II
Johnson & Johnson (JNJ): One of the Best Blue Chip Dividend Stocks Right Now According to Hedge Funds?
Johnson & Johnson (NYSE:JNJ) is an American pharmaceutical industry company that also specializes in healthcare consumer products.
Express News | On Monday, Johnson & Johnson Agreed To Pay $50M To Settle Claims Related To A Terminated Manufacturing Deal With Emergent BioSolutions Related To Johnson & Johnson's Covid-19 Vaccine - 8K
Emergent Biosolutions, Johnson & Johnson Settle Dispute Over COVID-19 Vaccine Manufacturing
Emergent Biosolutions (EBS) said in a regulatory filing Monday that its subsidiary, Emergent Manufacturing Operations Baltimore, and Johnson & Johnson's Janssen Pharmaceuticals unit have agreed to settle all disputes related to a manufacturing services agreement for Johnson & Johnson's COVID-19 vaccine.
Is the second bull market really here? The Nikkei rose 2% and hit a new high again.
Is the Japanese stock market starting a new bull market?
Express News | Emergent BioSolutions- Deal to Resolve Claims From Manufacturing Services Deal for J&J's Investigational Sars-Cov-2 Vaccine, Ad26.cov2-S, Recombinant
Goldman Sachs Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $160
Goldman Sachs analyst Chris Shibutani maintains $Johnson & Johnson(JNJ.US)$ with a hold rating, and maintains the target price at $160.According to TipRanks data, the analyst has a success rate of 44.
Express News | German Cartel Office: J&J Cleared to Take Over Shockwave Medical
Wells Fargo Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Announces Target Price $163
Wells Fargo analyst Larry Biegelsen maintains $Johnson & Johnson(JNJ.US)$ with a hold rating, and sets the target price at $163.According to TipRanks data, the analyst has a success rate of 58.5% and
Unusual Options Activity: JNJ, CSCO and Others Attract Market Bets, JNJ V/OI Ratio Reaches 153.8
EST Jul 5th Morning Delivery - In the last two hours of trading, 9 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.Of
What's Going On With Johnson and Johnson Shares Friday?
Johnson and Johnson (NYSE:JNJ) shares are trending on Friday. In the last week, the pharmaceutical company announced positive results from two clinical trials and authorization from Health Canada for
J&J (JNJ) Trades Below 200 & 50-Day Moving Averages: Buy the Dip?
ohnson & Johnson’s (JNJ Quick QuoteJNJ - Free Report) stock has been trading below its 200-day and 50-day moving averages since the end of June. On Jul 3, the stock’s closing price of $145.69 was below its 50-day moving average of $147.61 and the 200-day moving average of 151.95.
Johnson & Johnson's bispecific antibody drug talquetamab has been approved for sale in South Korea.
On July 2, Johnson & Johnson's (JNJ.US) South Korea company announced that its bispecific antibody drug Talquetamab has been approved for launch in South Korea.